Verrica Pharmaceuticals Inc. (VRCA) Form 10-Q — May 12, 2026
Verrica Pharmaceuticals Inc. reported a net loss of $9.7 million for the quarter ended March 31, 2026, with total revenue of $5.0 million, up from $3.4 million in the same period last year. The increase in revenue was primarily due to higher deliveries of YCANTH (VP-102) to distribution partners. The company's cash position as of March 31, 2026, was $20.6 million, down from $30.1 million at the end of 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 5023
- Total Debt
- 22731
- Revenue Yoy
- 1584
- Cash Position
- 20600
- Reverse split ratio
- 1:10
Price after filing
1 day: +3.1%7 days: -21.8%30 days: -19.6%
Close on the filing date to close N calendar days later (from $7.15). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.